Skip to main content
SpringerLink
Log in
Book cover

Lung Cancer and Personalized Medicine pp 189–209Cite as

Chemotherapy Resistance in Lung Cancer

  • Chapter
  • First Online:

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 893))

Abstract

Despite a growing interest in development of non-cytotoxic targeted agents, systemic chemotherapy is still the mainstay of treatment for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). However, chemotherapy resistance limits our ability to effectively treat advanced lung cancer. Some lung tumors are intrinsically resistant to chemotherapy, and in virtually all cases, even the initial responders rapidly develop acquired resistance. While targeting histology could result in enhanced tumor sensitivity to a particular chemotherapeutic agent, better understanding of molecular determinants of chemotherapy sensitivity/resistance would be critically important. Development of predictive biomarkers to personalize chemotherapeutic agents and combining novel agents targeting specific resistance pathways with standard chemotherapy could be some promising strategies to overcome chemotherapy resistance in lung cancer. In this chapter, we will discuss some key mechanisms of resistance for commonly used chemotherapeutic agents in lung cancer.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ (2008) Medical treatment of advanced testicular cancer. JAMA 299(6):672–684. doi:10.1001/jama.299.6.672

    Article  CAS  PubMed  Google Scholar 

  2. Gately DP, Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67(6):1171–1176

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Andrews PA, Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2(2):35–43

    CAS  PubMed  Google Scholar 

  4. Shellard SA, Fichtinger-Schepman AM, Lazo JS, Hill BT (1993) Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs 4(4):491–500

    Article  CAS  PubMed  Google Scholar 

  5. Kawai H, Kiura K, Tabata M, Yoshino T, Takata I, Hiraki A, Chikamori K, Ueoka H, Tanimoto M, Harada M (2002) Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy. Lung Cancer 35(3):305–314, S0169500201004305 [pii]

    Article  PubMed  Google Scholar 

  6. Bungo M, Fujiwara Y, Kasahara K, Nakagawa K, Ohe Y, Sasaki Y, Irino S, Saijo N (1990) Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res 50(9):2549–2553

    CAS  PubMed  Google Scholar 

  7. Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH (2012) Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol 30(27):3345–3352. doi:10.1200/JCO.2011.40.8120

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ishida S, Lee J, Thiele DJ, Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A 99(22):14298–14302. doi:10.1073/pnas.162491399162491399 [pii]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, Kuo MT (2004) Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 3(12):1543–1549, 3/12/1543 [pii]

    CAS  PubMed  Google Scholar 

  10. Chen HH, Yan JJ, Chen WC, Kuo MT, Lai YH, Lai WW, Liu HS, Su WC (2012) Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer 75(2):228–234. doi:10.1016/j.lungcan.2011.06.011

    Article  PubMed  Google Scholar 

  11. Ishida S, McCormick F, Smith-McCune K, Hanahan D (2010) Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 17(6):574–583. doi:10.1016/j.ccr.2010.04.011, S1535-6108(10)00150-9 [pii]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II (2009) Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 15(11):3881–3888. doi:10.1158/1078-0432.CCR-08-2196

    Article  CAS  PubMed  Google Scholar 

  13. Bando T, Fujimura M, Kasahara K, Ueno T, Matsuda T (2000) Selective beta2-adrenoceptor agonist enhances sensitivity to cisplatin in non-small cell lung cancer cell line. Oncol Rep 7(1):49–52

    CAS  PubMed  Google Scholar 

  14. Bando T, Fujimura M, Kasahara K, Matsuda T (1998) Significance of Na+, K(+)-ATPase on intracellular accumulation of cis-diamminedichloroplatinum(II) in human non-small-cell but not in small-cell lung cancer cell lines. Anticancer Res 18(2A):1085–1089

    CAS  PubMed  Google Scholar 

  15. Bando T, Fujimura M, Kasahara K, Matsuda T (1998) Role of thromboxane receptor on the intracellular accumulation of cis-diamminedichloroplatinum(II) in non-small-cell but not in small-cell lung cancer cell lines. Anticancer Res 18(2A):1079–1084

    CAS  PubMed  Google Scholar 

  16. Fujimura M, Kasahara K, Shirasaki H, Heki U, Iwasa K, Ueda A, Matsuda T (1999) Up-regulation of ICH-1L protein by thromboxane A2 antagonists enhances cisplatin-induced apoptosis in non-small-cell lung-cancer cell lines. J Cancer Res Clin Oncol 125(7):389–394

    Article  CAS  PubMed  Google Scholar 

  17. Bando T, Fujimura M, Kasahara K, Shibata K, Shirasaki H, Heki U, Iwasa K, Ueda A, Tomikawa S, Matsuda T (1997) Exposure to sorbitol induces resistance to cisplatin in human non-small-cell lung cancer cell lines. Anticancer Res 17(5A):3345–3348

    CAS  PubMed  Google Scholar 

  18. Tokuchi Y, Isobe H, Takekawa H, Hanada T, Ishida T, Ogura S, Itoh K, Furudate M, Saito K, Kawakami Y (1998) Predicting chemotherapeutic response to small-cell lung cancer of platinum compounds by thallium-201 single-photon emission computerized tomography. Br J Cancer 77(8):1363–1368

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Yamamoto Y, Nishiyama Y, Satoh K, Takashima H, Ohkawa M, Fujita J, Kishi T, Matsuno S, Tanabe M (1998) Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer. J Nucl Med 39(9):1626–1629

    CAS  PubMed  Google Scholar 

  20. Nakagawa T, Inoue Y, Kodama H, Yamazaki H, Kawai K, Suemizu H, Masuda R, Iwazaki M, Yamada S, Ueyama Y, Inoue H, Nakamura M (2008) Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts. Oncol Rep 20(2):265–270

    CAS  PubMed  Google Scholar 

  21. Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K, Nishiwaki Y, Kodama T, Suga M, Ochiai A (2004) Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 10(5):1691–1697

    Article  CAS  PubMed  Google Scholar 

  22. Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, Murata Y, Yamazaki M, Nishiwaki Y, Eguchi K, Ochiai A (2009) Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 64(1):98–104

    Article  PubMed  Google Scholar 

  23. Hu Y, Lin DM, Cheng SJ, Liu YN, Feng FY (2006) Influences of PC cell-derived growth factor and breast cancer resistance protein on the curative effects of platinum-based chemotherapeutic regimens for advanced non-small cell lung cancer. Zhonghua Yi Xue Za Zhi 86(37):2611–2614

    CAS  PubMed  Google Scholar 

  24. Hu Y, Feng FY, Cheng SJ, Gao YN, Xiao T, Liu YN (2006) Expression of serum breast drug-resistance protein in predicting chemosensitivity of NSCLC. Zhonghua Zhong Liu Za Zhi 28(10):750–752

    CAS  PubMed  Google Scholar 

  25. Meijer C, Mulder NH, Hospers GA, Uges DR, de Vries EG (1990) The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line. Br J Cancer 62(1):72–77

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Jain N, Lam YM, Pym J, Campling BG (1996) Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Cancer 77(9):1797–1808

    Article  CAS  PubMed  Google Scholar 

  27. Hospers GA, Meijer C, de Leij L, Uges DR, Mulder NH, de Vries EG (1990) A study of human small-cell lung carcinoma (hSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (CDDP) resistance. Int J Cancer 46(1):138–144

    Article  CAS  PubMed  Google Scholar 

  28. Moritaka T, Kiura K, Ueoka H, Tabata M, Segawa Y, Shibayama T, Takigawa N, Ohnoshi T, Harada M (1998) Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids. Anticancer Res 18(2A):927–933

    CAS  PubMed  Google Scholar 

  29. Fokkema E, Groen HJ, Helder MN, de Vries EG, Meijer C (2002) JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. Biochem Pharmacol 63(11):1989–1996

    Article  CAS  PubMed  Google Scholar 

  30. Oshita F, Fujiwara Y, Saijo N (1992) Radiation sensitivities in various anticancer-drug-resistant human lung cancer cell lines and mechanism of radiation cross-resistance in a cisplatin-resistant cell line. J Cancer Res Clin Oncol 119(1):28–34

    Article  CAS  PubMed  Google Scholar 

  31. Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG (1992) Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res 52(24):6885–6889

    CAS  PubMed  Google Scholar 

  32. Kurokawa H, Ishida T, Nishio K, Arioka H, Sata M, Fukumoto H, Miura M, Saijo N (1995) Gamma-glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. Biochem Biophys Res Commun 216(1):258–264

    Article  CAS  PubMed  Google Scholar 

  33. Zhan M, Liu X (1999) Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP. Chin Med J (Engl) 112(4):336–339

    CAS  Google Scholar 

  34. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265–7279. doi:10.1038/sj.onc.1206933

    Article  CAS  PubMed  Google Scholar 

  35. van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D, Bartelink H, Begg AC (2000) DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 89(2):160–166

    Article  PubMed  Google Scholar 

  36. Takenaka T, Yoshino I, Kouso H, Ohba T, Yohena T, Osoegawa A, Shoji F, Maehara Y (2007) Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer 121(4):895–900. doi:10.1002/ijc.22738

    Article  CAS  PubMed  Google Scholar 

  37. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, IB Investigators (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983–991. doi:10.1056/NEJMoa060570

    Article  CAS  PubMed  Google Scholar 

  38. Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N (2007) ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2(10):902–906. doi:10.1097/JTO.0b013e318155a637

    Article  PubMed  Google Scholar 

  39. Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour L, Pirker R, Filipits M, Andre F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria JC (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368(12):1101–1110. doi:10.1056/NEJMoa1214271

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR (2013) Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. doi:10.1200/JCO.2012.46.9783

    PubMed  PubMed Central  Google Scholar 

  41. Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, Matsuda T, Saijo N (1991) Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 51(12):3237–3242

    CAS  PubMed  Google Scholar 

  42. Joseph MG, Banerjee D, Kocha W, Feld R, Stitt LW, Cherian MG (2001) Metallothionein expression in patients with small cell carcinoma of the lung: correlation with other molecular markers and clinical outcome. Cancer 92(4):836–842

    Article  CAS  PubMed  Google Scholar 

  43. Goodsell DS (2000) The molecular perspective: microtubules and the taxanes. Oncologist 5(4):345–346

    Article  CAS  PubMed  Google Scholar 

  44. Verdier-Pinard P, Wang F, Martello L, Burd B, Orr GA, Horwitz SB (2003) Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry. Biochemistry 42(18):5349–5357

    Article  CAS  PubMed  Google Scholar 

  45. Han EK, Gehrke L, Tahir SK, Credo RB, Cherian SP, Sham H, Rosenberg SH, Ng S (2000) Modulation of drug resistance by alpha-tubulin in paclitaxel-resistant human lung cancer cell lines. Eur J Cancer 36(12):1565–1571

    Article  CAS  PubMed  Google Scholar 

  46. Kavallaris M, Burkhart CA, Horwitz SB (1999) Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 80(7):1020–1025

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Zeng L, Kizaka-Kondoh S, Itasaka S, Xie X, Inoue M, Tanimoto K, Shibuya K, Hiraoka M (2007) Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions. Cancer Sci 98(9):1394–1401

    Article  CAS  PubMed  Google Scholar 

  48. Goncalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S, Wilson L, Jordan MA (2001) Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci U S A 98(20):11737–11742

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Marcus AI, Zhou J, O’Brate A, Hamel E, Wong J, Nivens M, El-Naggar A, Yao TP, Khuri FR, Giannakakou P (2005) The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res 65(9):3883–3893

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Dumontet C, Isaac S, Souquet PJ, Bejui-Thivolet F, Pacheco Y, Peloux N, Frankfurter A, Luduena R, Perol M (2005) Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 92(2):E25–E30

    PubMed  Google Scholar 

  51. Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, Lai R, Voloch A, Dumontet C (2005) Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4(12):2001–2007

    Article  CAS  PubMed  Google Scholar 

  52. Monzo M, Rosell R, Sanchez JJ, Lee JS, O’Brate A, Gonzalez-Larriba JL, Alberola V, Lorenzo JC, Nunez L, Ro JY, Martin C (1999) Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17(6):1786–1793

    Article  CAS  PubMed  Google Scholar 

  53. Masuda A, Maeno K, Nakagawa T, Saito H, Takahashi T (2003) Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am J Pathol 163(3):1109–1116. doi:10.1016/S0002-9440(10)63470-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Pommier Y, Leo E, Zhang H, Marchand C (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17(5):421–433. doi:10.1016/j.chembiol.2010.04.012

    Article  CAS  PubMed  Google Scholar 

  55. Kasahara K, Fujiwara Y, Sugimoto Y, Nishio K, Tamura T, Matsuda T, Saijo N (1992) Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J Natl Cancer Inst 84(2):113–118

    Article  CAS  PubMed  Google Scholar 

  56. Tsujino I, Yamazaki T, Masutani M, Sawada U, Horie T (1999) Effect of Tween-80 on cell killing by etoposide in human lung adenocarcinoma cells. Cancer Chemother Pharmacol 43(1):29–34

    Article  CAS  PubMed  Google Scholar 

  57. Belanger MM, Gaudreau M, Roussel E, Couet J (2004) Role of caveolin-1 in etoposide resistance development in A549 lung cancer cells. Cancer Biol Ther 3(10):954–959

    Article  CAS  PubMed  Google Scholar 

  58. Yamazaki K, Isobe H, Hanada T, Betsuyaku T, Hasegawa A, Hizawa N, Ogura S, Kawakami Y (1997) Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines. Cancer Chemother Pharmacol 39(3):192–198

    Article  CAS  PubMed  Google Scholar 

  59. Houlbrook S, Harris AL, Carmichael J, Stratford IJ (1996) Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell lines. Anticancer Res 16(4A):1603–1610

    CAS  PubMed  Google Scholar 

  60. Andoh T, Nishizawa M, Hida T, Ariyoshi Y, Takahashi T, Ueda R (1996) Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection. Oncol Res 8(6):229–238

    CAS  PubMed  Google Scholar 

  61. Guinee DG Jr, Holden JA, Benfield JR, Woodward ML, Przygodzki RM, Fishback NF, Koss MN, Travis WD (1996) Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response. Cancer 78(4):729–735

    Article  PubMed  Google Scholar 

  62. Kreisholt J, Sorensen M, Jensen PB, Nielsen BS, Andersen CB, Sehested M (1998) Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer. Br J Cancer 77(9):1469–1473

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Hansen LT, Lundin C, Spang-Thomsen M, Petersen LN, Helleday T (2003) The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer 105(4):472–479

    Article  CAS  PubMed  Google Scholar 

  64. Kraus AC, Ferber I, Bachmann SO, Specht H, Wimmel A, Gross MW, Schlegel J, Suske G, Schuermann M (2002) In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 21(57):8683–8695

    Article  CAS  PubMed  Google Scholar 

  65. Lee SM, Lee CT, Kim YW, Han SK, Shim YS, Yoo CG (2006) Hypoxia confers protection against apoptosis via PI3K/Akt and ERK pathways in lung cancer cells. Cancer Lett 242(2):231–238

    Article  CAS  PubMed  Google Scholar 

  66. Shimoda R, Achanzar WE, Qu W, Nagamine T, Takagi H, Mori M, Waalkes MP (2003) Metallothionein is a potential negative regulator of apoptosis. Toxicol Sci 73(2):294–300

    Article  CAS  PubMed  Google Scholar 

  67. Smith GC, Jackson SP (1999) The DNA-dependent protein kinase. Genes Dev 13(8):916–934

    Article  CAS  PubMed  Google Scholar 

  68. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17(Suppl 5):v7–v12. doi:10.1093/annonc/mdj941

    Article  PubMed  Google Scholar 

  69. Seve P, Mackey JR, Isaac S, Tredan O, Souquet PJ, Perol M, Cass C, Dumontet C (2005) cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer 49(3):363–370

    Article  PubMed  Google Scholar 

  70. Kim MJ, Lee HJ, Lee IA, Kim IY, Lim SK, Cho HA, Kim JS (2008) Preparation of pH-sensitive, long-circulating and EGFR-targeted immunoliposomes. Arch Pharm Res 31(4):539–546

    Article  CAS  PubMed  Google Scholar 

  71. Oguri T, Achiwa H, Muramatsu H, Ozasa H, Sato S, Shimizu S, Yamazaki H, Eimoto T, Ueda R (2007) The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett 256(1):112–119

    Article  CAS  PubMed  Google Scholar 

  72. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, Simon G (2006) RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24(29):4731–4737

    Article  CAS  PubMed  Google Scholar 

  73. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA (2004) An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 64(11):3761–3766

    Article  CAS  PubMed  Google Scholar 

  74. Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, Jung JJ, Kim TS, Jeung HC, Chung HC (2006) Ribonucleotide reductase M1 (RRM1) 2464G > A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics 16(6):429–438

    Article  CAS  PubMed  Google Scholar 

  75. Tooker P, Yen WC, Ng SC, Negro-Vilar A, Hermann TW (2007) Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res 67(9):4425–4433

    Article  CAS  PubMed  Google Scholar 

  76. Oguri T, Achiwa H, Sato S, Bessho Y, Takano Y, Miyazaki M, Muramatsu H, Maeda H, Niimi T, Ueda R (2006) The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol Cancer Ther 5(7):1800–1806

    Article  CAS  PubMed  Google Scholar 

  77. Shimizu J, Horio Y, Osada H, Hida T, Hasegawa Y, Shimokata K, Takahashi T, Sekido Y, Yatabe Y (2008) mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology 13(4):510–517

    Article  PubMed  Google Scholar 

  78. Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M, Queralt C, Sanchez JJ, Maestre J (2004) Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 10(12 Pt 2):4215s–4219s

    Article  CAS  PubMed  Google Scholar 

  79. Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S, Cooc J, Crino L, Sanchez JJ, Taron M, Boni C, De Marinis F, Tonato M, Marangolo M, Gozzelino F, Di Costanzo F, Rinaldi M, Salonga D, Stephens C (2003) Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22(23):3548–3553

    Article  CAS  PubMed  Google Scholar 

  80. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10(4):1318–1325

    Article  CAS  PubMed  Google Scholar 

  81. Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M, Scagliotti GV (2006) ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17(12):1818–1825

    Article  CAS  PubMed  Google Scholar 

  82. Souglakos J, Boukovinas I, Taron M, Mendez P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulias V, Rosell R (2008) Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 98(10):1710–1715

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Stuckler D, Singhal J, Singhal SS, Yadav S, Awasthi YC, Awasthi S (2005) RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer. Cancer Res 65(3):991–998

    CAS  PubMed  Google Scholar 

  84. Gregory RK, Smith IE (2000) Vinorelbine–a clinical review. Br J Cancer 82(12):1907–1913. doi:10.1054/bjoc.2000.1203

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Archambault V, Glover DM (2009) Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 10(4):265–275. doi:10.1038/nrm2653, nrm2653 [pii]

    Article  CAS  PubMed  Google Scholar 

  86. Zhou Q, Bai M, Su Y (2004) Effect of antisense RNA targeting polo-like kinase 1 on cell cycle and proliferation in A549 cells. Chin Med J (Engl) 117(11):1642–1649

    CAS  Google Scholar 

  87. Seve P, Isaac S, Tredan O, Souquet PJ, Pacheco Y, Perol M, Lafanechere L, Penet A, Peiller EL, Dumontet C (2005) Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11(15):5481–5486

    Article  CAS  PubMed  Google Scholar 

  88. Seve P, Lai R, Ding K, Winton T, Butts C, Mackey J, Dumontet C, Dabbagh L, Aviel-Ronen S, Seymour L, Whitehead M, Tsao MS, Shepherd FA, Reiman T (2007) Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 13(3):994–999

    Article  CAS  PubMed  Google Scholar 

  89. Nishio K, Nakamura T, Koh Y, Kanzawa F, Tamura T, Saijo N (2001) Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells. Cancer 91(8):1494–1499

    Article  CAS  PubMed  Google Scholar 

  90. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21):3543–3551

    Article  CAS  PubMed  Google Scholar 

  91. Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, Goldman ID (2008) The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol 74(3):854–862. doi:10.1124/mol.108.045443, mol.108.045443 [pii]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Chattopadhyay S, Wang Y, Zhao R, Goldman ID (2004) Lack of impact of the loss of constitutive folate receptor alpha expression, achieved by RNA Interference, on the activity of the new generation antifolate pemetrexed in HeLa cells. Clin Cancer Res 10(23):7986–7993. doi:10.1158/1078-0432.CCR-04-1225, 10/23/7986 [pii]

    Article  CAS  PubMed  Google Scholar 

  93. Theti DS, Jackman AL (2004) The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs. Clin Cancer Res 10(3):1080–1089

    Article  CAS  PubMed  Google Scholar 

  94. Nunez MI, Behrens C, Woods DM, Lin H, Prudkin L, Suraokar M, Girard L, Minna JD, Lee JJ, Hofstetter W, Franklin W, Moran CA, Stewart DJ, Wistuba II (2009) Immunohistochemical expression of membrane transporters correlates with histology type of non-small cell lung carcinoma. In: Proceedings of the 100th annual meeting of the American Association of Cancer Research: Abstract #1594

    Google Scholar 

  95. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R (2005) Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68(1):110–118

    CAS  PubMed  Google Scholar 

  96. Liu Y, Yin TJ, Zhou R, Zhou S, Fan L, Zhang RG (2013) Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis. Cancer Chemother Pharmacol 72(5):1125–1132. doi:10.1007/s00280-013-2299-2

    Article  CAS  PubMed  Google Scholar 

  97. Chattopadhyay S, Tamari R, Min SH, Zhao R, Tsai E, Goldman ID (2007) Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. Oncologist 12(7):808–815

    Article  CAS  PubMed  Google Scholar 

  98. Stewart DJ (2010) Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 75(3):173–234. doi:10.1016/j.critrevonc.2009.11.006, S1040-8428(09)00230-3 [pii]

    Article  PubMed  PubMed Central  Google Scholar 

  99. Stewart DJ, Tomiak E, Shamji FM, Maziak DE, MacLeod P (2004) Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer. Lung Cancer 44(2):241–249. doi:10.1016/j.lungcan.2003.10.009, S0169500203005592 [pii]

    Article  PubMed  Google Scholar 

  100. Giaccone G, van Ark-Otte J, Rubio GJ, Gazdar AF, Broxterman HJ, Dingemans AM, Flens MJ, Scheper RJ, Pinedo HM (1996) MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs. Int J Cancer 66(6):760–767

    Article  CAS  PubMed  Google Scholar 

  101. Campling BG, Young LC, Baer KA, Lam YM, Deeley RG, Cole SP, Gerlach JH (1997) Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin Cancer Res 3(1):115–122

    CAS  PubMed  Google Scholar 

  102. Bessho Y, Oguri T, Ozasa H, Uemura T, Sakamoto H, Miyazaki M, Maeno K, Sato S, Ueda R (2009) ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer. Oncol Rep 21(1):263–268

    CAS  PubMed  Google Scholar 

  103. Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH (2001) Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 7(6):1798–1804

    CAS  PubMed  Google Scholar 

  104. Narasaki F, Oka M, Fukuda M, Ikeda K, Terashi K, Takatani H, Nakamura T, Soda H, Kohno S (1997) Multidrug resistance-associated protein gene expression and drug sensitivity in human lung cancer cells. Anticancer Res 17(5A):3493–3497

    CAS  PubMed  Google Scholar 

  105. Henness S, Davey MW, Harvie RM, Davey RA (2002) Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase IIalpha expression. Int J Radiat Oncol Biol Phys 54(3):895–902

    Article  CAS  PubMed  Google Scholar 

  106. Oguri T, Ozasa H, Uemura T, Bessho Y, Miyazaki M, Maeno K, Maeda H, Sato S, Ueda R (2008) MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Mol Cancer Ther 7(5):1150–1155

    Article  CAS  PubMed  Google Scholar 

  107. Gonzalez Manzano R, Versanvoort C, Wright K, Twentyman PR (1996) Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell line. Eur J Cancer 32A(12):2136–2141

    Article  CAS  PubMed  Google Scholar 

  108. Zaman GJ, Lankelma J, van Tellingen O, Beijnen J, Dekker H, Paulusma C, Oude Elferink RP, Baas F, Borst P (1995) Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci U S A 92(17):7690–7694

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Liang Y, O’Driscoll L, McDonnell S, Doolan P, Oglesby I, Duffy K, O’Connor R, Clynes M (2004) Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer 111(4):484–493

    Article  CAS  PubMed  Google Scholar 

  110. Ikuta K, Takemura K, Sasaki K, Kihara M, Nishimura M, Ueda N, Naito S, Lee E, Shimizu E, Yamauchi A (2005) Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells. Biol Pharm Bull 28(4):707–712

    Article  CAS  PubMed  Google Scholar 

  111. van Ark-Otte J, Samelis G, Rubio G, Lopez Saez JB, Pinedo HM, Giaccone G (1998) Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep 5(1):249–255

    PubMed  Google Scholar 

  112. Bergman AM, Pinedo HM, Talianidis I, Veerman G, Loves WJ, van der Wilt CL, Peters GJ (2003) Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer 88(12):1963–1970

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Xu M, Li J, Xia Q (1999) Expression of multidrug resistance-associated protein gene in non-small cell lung cancer. Zhonghua Jie He He Hu Xi Za Zhi 22(5):268–270

    CAS  PubMed  Google Scholar 

  114. Oshika Y, Nakamura M, Tokunaga T, Fukushima Y, Abe Y, Ozeki Y, Yamazaki H, Tamaoki N, Ueyama Y (1998) Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer. Mod Pathol 11(11):1059–1063

    CAS  PubMed  Google Scholar 

  115. Ota E, Abe Y, Oshika Y, Ozeki Y, Iwasaki M, Inoue H, Yamazaki H, Ueyama Y, Takagi K, Ogata T et al (1995) Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer 72(3):550–554

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Triller N, Korosec P, Kern I, Kosnik M, Debeljak A (2006) Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer 54(2):235–240

    Article  PubMed  Google Scholar 

  117. Yeh JJ, Hsu NY, Hsu WH, Tsai CH, Lin CC, Liang JA (2005) Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. Lung 183(3):177–183

    Article  CAS  PubMed  Google Scholar 

  118. Ushijima R, Takayama K, Izumi M, Harada T, Horiuchi Y, Uchino J, Hara N, Nakanishi Y (2007) Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer. Anticancer Res 27(6C):4351–4358

    CAS  PubMed  Google Scholar 

  119. Oguri T, Isobe T, Fujitaka K, Ishikawa N, Kohno N (2001) Association between expression of the MRP3 gene and exposure to platinum drugs in lung cancer. Int J Cancer 93(4):584–589

    Article  CAS  PubMed  Google Scholar 

  120. Oguri T, Isobe T, Suzuki T, Nishio K, Fujiwara Y, Katoh O, Yamakido M (2000) Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer. Int J Cancer 86(1):95–100

    Article  CAS  PubMed  Google Scholar 

  121. Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee JE, Lee DH, Kim HT, Lee JS (2007) Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110(1):138–147

    Article  PubMed  Google Scholar 

  122. Dingemans AC, van Ark-Otte J, Span S, Scagliotti GV, van der Valk P, Postmus PE, Giaccone G (2001) Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer. Lung Cancer 32(2):117–128

    Article  CAS  PubMed  Google Scholar 

  123. Wang J, Liu X, Jiang W (2000) Expression of LRP, MRP and MDR1 in non-small-cell lung cancer and its clinical significance. Zhonghua Zhong Liu Za Zhi 22(4):304–307

    CAS  PubMed  Google Scholar 

  124. Filipits M, Haddad V, Schmid K, Huynh A, Dunant A, Andre F, Brambilla E, Stahel R, Pignon JP, Soria JC, Popper HH, Le Chevalier T, Pirker R (2007) Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res 13(13):3892–3898

    Article  CAS  PubMed  Google Scholar 

  125. NicAmhlaoibh R, Heenan M, Cleary I, Touhey S, O’Loughlin C, Daly C, Nunez G, Scanlon KJ, Clynes M (1999) Altered expression of mRNAs for apoptosis-modulating proteins in a low level multidrug resistant variant of a human lung carcinoma cell line that also expresses mdr1 mRNA. Int J Cancer 82(3):368–376

    Article  CAS  PubMed  Google Scholar 

  126. Yabuki N, Sakata K, Yamasaki T, Terashima H, Mio T, Miyazaki Y, Fujii T, Kitada K (2007) Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genet Cytogenet 173(1):1–9

    Article  CAS  PubMed  Google Scholar 

  127. Pesic M, Markovic JZ, Jankovic D, Kanazir S, Markovic ID, Rakic L, Ruzdijic S (2006) Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. J Chemother 18(1):66–73

    Article  CAS  PubMed  Google Scholar 

  128. Sato H, Fukumoto K, Hada S, Hagiwara H, Fujimoto E, Negishi E, Ueno K, Yano T (2007) Enhancing effect of connexin 32 gene on vinorelbine-induced cytotoxicity in A549 lung adenocarcinoma cells. Cancer Chemother Pharmacol 60(3):449–457

    Article  CAS  PubMed  Google Scholar 

  129. Ji D, Deeds SL, Weinstein EJ (2007) A screen of shRNAs targeting tumor suppressor genes to identify factors involved in A549 paclitaxel sensitivity. Oncol Rep 18(6):1499–1505

    CAS  PubMed  Google Scholar 

  130. Kitazaki T, Oka M, Nakamura Y, Tsurutani J, Doi S, Yasunaga M, Takemura M, Yabuuchi H, Soda H, Kohno S (2005) Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49(3):337–343

    Article  PubMed  Google Scholar 

  131. Glisson BS, Alpeter MD (1992) Multidrug resistance in a small cell lung cancer line: rapid selection with etoposide and differential chemosensitization with cyclosporin A. Anticancer Drugs 3(4):359–366

    Article  CAS  PubMed  Google Scholar 

  132. Takigawa N, Ohnoshi T, Ueoka H, Kiura K, Kimura I (1992) Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line. Acta Med Okayama 46(3):203–212

    CAS  PubMed  Google Scholar 

  133. Xia S, Yu SY, Yuan XL, Xu SP (2004) Effects of hypoxia on expression of P-glycoprotein and multidrug resistance protein in human lung adenocarcinoma A549 cell line. Zhonghua Yi Xue Za Zhi 84(8):663–666

    CAS  PubMed  Google Scholar 

  134. Yasuda H, Nakayama K, Watanabe M, Suzuki S, Fuji H, Okinaga S, Kanda A, Zayasu K, Sasaki T, Asada M, Suzuki T, Yoshida M, Yamanda S, Inoue D, Kaneta T, Kondo T, Takai Y, Sasaki H, Yanagihara K, Yamaya M (2006) Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. Clin Cancer Res 12(22):6748–6757

    Article  CAS  PubMed  Google Scholar 

  135. Oka M, Fukuda M, Sakamoto A, Takatani H, Fukuda M, Soda H, Kohno S (1997) The clinical role of MDR1 gene expression in human lung cancer. Anticancer Res 17(1B):721–724

    CAS  PubMed  Google Scholar 

  136. Inoue Y, Gika M, Abiko T, Oyama T, Saitoh Y, Yamazaki H, Nakamura M, Abe Y, Kawamura M, Kobayashi K (2005) Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer. Oncol Rep 13(2):259–264

    CAS  PubMed  Google Scholar 

  137. Peng ZM, Luo J, Wang WB, Wang XH, Chen JH, Lan SM (2004) Predictive value of drug resistance-related genes expression in neoadjuvant chemotherapy in patients with non-small cell lung cancer of stage III. Ai Zheng 23(8):963–967

    PubMed  Google Scholar 

  138. Kawasaki M, Nakanishi Y, Kuwano K, Takayama K, Kiyohara C, Hara N (1998) Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer 34(9):1352–1357

    Article  CAS  PubMed  Google Scholar 

  139. Kao A, Shiun SC, Hsu NY, Sun SS, Lee CC, Lin CC (2001) Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression. Ann Oncol 12(11):1561–1566

    Article  CAS  PubMed  Google Scholar 

  140. Yeh JJ, Hsu WH, Huang WT, Wang JJ, Ho ST, Kao A (2003) Technetium-99m tetrofosmin SPECT predicts chemotherapy response in small cell lung cancer. Tumour Biol 24(3):151–155

    Article  PubMed  Google Scholar 

  141. Savaraj N, Wu CJ, Xu R, Lampidis T, Lai S, Donnelly E, Solomon J, Feun LG (1997) Multidrug-resistant gene expression in small-cell lung cancer. Am J Clin Oncol 20(4):398–403

    Article  CAS  PubMed  Google Scholar 

  142. Sohn JW, Lee SY, Lee SJ, Kim EJ, Cha SI, Kim CH, Lee JT, Jung TH, Park JY (2006) MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 36(3):137–141

    Article  PubMed  Google Scholar 

  143. Hsu WH, Yen RF, Kao CH, Shiun SC, Hsu NY, Lin CC, Lee CC (2002) Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer (stage IIIb or IV) with a higher T stage (>T2). Technetium-99m methoxyisobutylisonitrile chest single photon emission computed tomography and P-glycoprotein express ion. Oncology 63(2):173–179

    Article  CAS  PubMed  Google Scholar 

  144. Yeh JJ, Hsu WH, Wang JJ, Ho ST, Kao A (2003) Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Respiration 70(1):32–35

    Article  CAS  PubMed  Google Scholar 

  145. Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN, Yu QZ (2008) MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 75(4):380–385

    Article  CAS  PubMed  Google Scholar 

  146. Miyatake K, Gemba K, Ueoka H, Nishii K, Kiura K, Tabata M, Shibayama T, Takigawa N, Kawaraya M, Tanimoto M (2003) Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer. Anticancer Res 23(3C):2829–2836

    CAS  PubMed  Google Scholar 

  147. Brooks KR, To K, Joshi MB, Conlon DH, Herndon JE 2nd, D’Amico TA, Harpole DH Jr (2003) Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. Ann Thorac Surg 76(1):187–193, discussion 193

    Article  PubMed  Google Scholar 

  148. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nunez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A, Medina B, Artal A, Lianes P (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15(8):1194–1203

    Article  CAS  PubMed  Google Scholar 

  149. Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, Whang-Peng J, Yang PC (2005) Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 65(15):6943–6949

    Article  CAS  PubMed  Google Scholar 

  150. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1. J Clin Oncol 22(5):777–784

    Article  CAS  PubMed  Google Scholar 

  151. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2. J Clin Oncol 22(5):785–794

    Article  CAS  PubMed  Google Scholar 

  152. Kruijtzer CM, Schellens JH, Mezger J, Scheulen ME, Keilholz U, Beijnen JH, Rosing H, Mathot RA, Marcus S, van Tinteren H, Baas P (2002) Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J Clin Oncol 20(23):4508–4516

    Article  CAS  PubMed  Google Scholar 

  153. Ross HJ, Cho J, Osann K, Wong SF, Ramsinghani N, Williams J, Downey-Hurtado N, Slater LM (1997) Phase I/II trial of low dose cyclosporin A with EP for advanced non-small cell lung cancer. Lung Cancer 18(2):189–198, S0169-5002(97)00061-5[pii]

    Article  CAS  PubMed  Google Scholar 

  154. Christen RD, Shalinsky DR, Howell SB (1992) Enhancement of the loss of multiple drug resistance by hydroxyurea. Semin Oncol 19(3 Suppl 9):94–100

    CAS  PubMed  Google Scholar 

  155. Stewart DJ, Tomiak EM, Goss G, Gertler SZ, Logan D, Huan S, Yau J, Dulude H, Evans WK (1996) Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer. Lung Cancer 15(1):115–123, 0169500296005764 [pii]

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA

    Eric S. Kim

Authors
  1. Eric S. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric S. Kim .

Editor information

Editors and Affiliations

  1. Wayne State University, Karmanos Cancer Institute, Detroit, Michigan, USA

    Aamir Ahmad

  2. Wayne State University, Karmanos Cancer Institute, Detroit, Michigan, USA

    Shirish Gadgeel

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Kim, E.S. (2016). Chemotherapy Resistance in Lung Cancer. In: Ahmad, A., Gadgeel, S. (eds) Lung Cancer and Personalized Medicine. Advances in Experimental Medicine and Biology, vol 893. Springer, Cham. https://doi.org/10.1007/978-3-319-24223-1_10

Download citation

Publish with us

Policies and ethics

Search

Navigation